Supplemental Online Content

Rezaei SJ, Chen ML, Kim J, John EM, Sunwoo JB, Linos E. The development of melanoma and other nonkeratinocyte skin cancers after thyroid cancer radiation. *JAMA Netw Open.* 2024;7(9):e2434841. doi:10.1001/jamanetworkopen.2024.34841

eMethods.

eTable. Other Nonkeratinocyte Skin Cancer Subtypes After Primary Thyroid Cancer, Diagnosed From 2000 to 2020

This supplemental material has been provided by the authors to give readers additional information about their work.

eMethods

The Multiple Primary-Standardized Incidence Ratios (MP-SIR) session was used to conduct the statistical analysis using SEER*Stat software (version 8.4.3, Surveillance Research Program, National Cancer Institute, Bethesda, MD, USA). Statistical significance was determined by a p-value <0.05. Radiation treatment that was listed as radioisotope in SEER was considered radioactive iodine therapy. Cancer diagnoses were identified using the International Classification of Diseases for Oncology, third edition (ICD-O-3) Site Recode/ World Health Organization (WHO) 2008 Definition. The analysis was performed January 2024 to April 2024. The Stanford IRB deemed this study exempt from review due to the use of only deidentified data. Subtypes included in our study are as follows:

eTable. Other Nonkeratinocyte Skin Cancer Subtypes After Primary Thyroid Cancer, Diagnosed From 2000 to 2020 ICD-O-3 code

8247/3: Merkel cell carcinoma

8410/3: Sebaceous adenocarcinoma

8832/3: Dermatofibrosarcoma, NOS

8413/3: Eccrine adenocarcinoma

8200/3: Adenoid cystic carcinoma

8402/3: Nodular hidradenoma, malignant

8800/3: Sarcoma, NOS

8390/3: Skin appendage carcinoma

8480/3: Mucinous adenocarcinoma

8542/3: Paget disease, extramammary (except Paget disease of bone)

8890/3: Leiomyosarcoma, NOS

8255/3: Adenocarcinoma with mixed subtypes

8407/3: Sclerosing sweat duct carcinoma

8430/3: Mucoepidermoid carcinoma

8830/3: Malignant fibrous histiocytoma

8833/3: Pigmented dermatofibrosarcoma protuberans

9120/3: Hemangiosarcoma